Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Regina Elena Cancer Institute
- Target Recruit Count
- 104
- Registration Number
- NCT00927511
- Locations
- 🇮🇹
Regina Elena Cancer Institute, Rome, RM, Italy
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 42
- Registration Number
- NCT00921115
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00903006
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 120
- Registration Number
- NCT00871858
- Locations
- 🇫🇷
Institut Bergonie, Bordeaux, France
Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2011-03-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT00774878
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT00754325
- Locations
- 🇺🇸
Kansas City Cancer Center, Llc., Overland Park, Kansas, United States
🇺🇸Northern Arizona Hematology & Oncology Associates, Sedona, Arizona, United States
🇺🇸Us Oncology Research, Inc., Houston, Texas, United States
ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 39
- Registration Number
- NCT00752986
- Locations
- 🇮🇹
Research Site, Varese, Italy
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 93
- Registration Number
- NCT00728949
- Locations
- 🇺🇸
ImClone Investigational Site, Nashville, Tennessee, United States
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
- First Posted Date
- 2008-07-25
- Last Posted Date
- 2018-02-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT00722072
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Gruppo Italiano Mammella (GIM)
- Target Recruit Count
- 396
- Registration Number
- NCT00688194
- Locations
- 🇮🇹
Federico II University Medical School, Naples, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.